Design and Synthesis of Fibroblast MULTIVALENT Drugs and Imaging Agents

Back to all technologies

Bookmark/Download	Download as PDF
Track Code	2019-LOW-68745
Categories	Chemistry and Chemical Analysis Pharmaceuticals
Keywords	Chemistry and Chemical Analysis Drug Development fibrosis Fibrotic Disease Idiopathic Pulmonary Fibrosis Medicinal Chemistry Patient Care Pharmaceutical Research Pharmaceuticals
Public Abstract	Researchers at Purdue University have developed two new drugs to treat idiopathic pulmonary fibrosis (IPF). IPF leads to gradual stiffening of the lungs until no gas exchange can occur. There remains an unmet need for treating patients with IPF as current drug candidates including pirfenidone and nintedanib generally exhibit minimal efficacy and may only delay but not prevent disease progression. The new drug candidates created by Purdue researchers target IPF pathologies by delivering therapeutic payloads specifically to two cell types, the infiltrating profibrotic macrophages and the fibrosis-producing myofibroblasts. By targeting the drugs to these two cell types the researchers are able to minimize toxicity to healthy tissues, thereby rendering the drugs much safer than traditional nontargeted therapies. Advantages: -Significant improvement in potency -Can minimize toxicity Potential Applications: -Drug discovery -Treating idiopathic pulmonary fibrosis Technology Validation: Gaining funding for preclinical trials
People	Low, Philip Stewart (Project leader) Mukkamala, Ramesh Srinivasarao, Madduri
Intellectual Property	Application Date Oct 19, 2022 Type Foreign, Non-PCT Country of Filing Hong Kong Patent Number (None) Issue Date (None) Application Date Sep 30, 2022 Type Foreign, Non-PCT Country of Filing Hong Kong Patent Number (None) Issue Date (None) Application Date Jan 21, 2022 Type NATL-Patent Country of Filing United States Patent Number (None) Issue Date (None) Application Date Jul 22, 2020 Type PCT-Patent Country of Filing WO Patent Number (None) Issue Date (None) Application Date Jul 22, 2020 Type NATL-Patent Country of Filing Europe Patent Number (None) Issue Date (None) Application Date Jul 22, 2020 Type NATL-Patent Country of Filing China Patent Number (None) Issue Date (None) Application Date Jul 22, 2020 Type NATL-Patent Country of Filing Japan Patent Number (None) Issue Date (None) Application Date Jul 22, 2020 Type NATL-Patent Country of Filing Australia Patent Number (None) Issue Date (None) Application Date Jul 22, 2020 Type NATL-Patent Country of Filing Canada Patent Number (None) Issue Date (None) Application Date Nov 11, 2019 Type Provisional-Patent Country of Filing United States Patent Number (None) Issue Date (None) Application Date Oct 4, 2019 Type Provisional-Patent Country of Filing United States Patent Number (None) Issue Date (None) Application Date Jul 22, 2019 Type Provisional-Patent Country of Filing United States Patent Number (None) Issue Date (None)
Contact OTC	Purdue Office of Technology Commercialization The Convergence Center 101 Foundry Drive, Suite 2500 West Lafayette, IN 47906 Phone: (765) 588-3475 Fax: (765) 463-3486 Email: otcip@prf.org